Teriparatide is a medication used to treat osteoporosis in postmenopausal women and men at high risk for fracture, as well as osteoporosis in men and women with high fracture risk who have a history of fracture caused by osteoporosis [1]. It is also indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture [1].
What is Teriparatide's Mechanism of Action?
Teriparatide is a potent anabolic agent that stimulates bone formation [2]. It is a recombinant form of parathyroid hormone (PTH) and is administered daily by subcutaneous injection [3]. By acting on bone, teriparatide increases bone mineral density (BMD) and reduces the incidence of fractures [2].
How is Teriparatide Administered and What is the Typical Dosage?
Teriparatide is administered as a daily subcutaneous injection. The typical dose for treating osteoporosis is 20 mcg once daily [1]. Treatment duration is generally limited to 2 years [4].
What are the Potential Side Effects of Teriparatide?
Common side effects of teriparatide include nausea, dizziness, leg cramps, and pain at the injection site [1]. Some patients may experience orthostatic hypotension, characterized by a drop in blood pressure upon standing, particularly during the initial doses [1]. Rare but serious side effects include osteosarcoma, a type of bone cancer, which has been observed in animal studies [1].
When Does Teriparatide's Patent Protection Expire?
Information regarding the specific patent expiry dates for teriparatide can be found on DrugPatentWatch.com [5]. Patent protection is crucial for pharmaceutical companies as it grants exclusive marketing rights for a period, allowing them to recoup research and development costs.
Can Biosimilars of Teriparatide Be Developed?
The development of biosimilars for biologic drugs like teriparatide is possible after patent expiry and loss of market exclusivity [5]. Biosimilars are highly similar to the reference biologic product, with no clinically meaningful differences in terms of safety, purity, and potency [5]. The availability of biosimilars can increase competition and potentially lower medication costs.
What is the Regulatory Status of Teriparatide?
Teriparatide is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for its indicated uses [1]. The drug's safety and efficacy have been established through clinical trials.
How Does Teriparatide Compare to Other Osteoporosis Medications?
Teriparatide is an anabolic agent, meaning it actively builds bone, which differentiates it from antiresorptive agents like bisphosphonates that primarily slow bone loss [3]. Its unique mechanism can lead to significant increases in bone density and reductions in fracture risk, particularly in patients with severe osteoporosis [3].
What Clinical Data Supports Teriparatide's Use?
Clinical trials have demonstrated that teriparatide significantly reduces the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [2]. Studies have also shown improvements in bone mineral density at the lumbar spine and hip [2].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021324s006lbl.pdf
2. https://pubmed.ncbi.nlm.nih.gov/15985352/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870488/
4. https://www.uptodate.com/contents/osteoporosis-treatment-with-parathyroid-hormone-and-related-therapies
5. https://drugpatentwatch.com/